---
schema_version: "secwatch.filing_event.v1"
accession: "0001655759-24-000128"
form_type: "8-K"
ticker: "ARVN"
cik: "0001655759"
company_name: "ARVINAS, INC."
filed_at: "2024-10-30T23:59:59+00:00"
generated_at: "2026-05-30T08:19:59.721041+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Arvinas Q3 2024 revenue $102.4M; cash $1.12B; VERITAC-2 data on track 4Q24/1Q25

## Summary
- Q3 revenue $102.4M (vs $34.6M YoY) mainly from Novartis license $76.7M.
- Cash and marketable securities $1.12B; sufficient to fund operations into 2027.
- R&D $86.9M; G&A $75.8M incl. $43.4M lease termination loss.
- VERITAC-2 Phase 3 topline data on track for 4Q24/1Q25; abemaciclib data at SABCS Dec 2024.
- ARV-102 MAD portion started; KRAS G12D IND filing expected 2025.

## SEC filing metadata
- accession: 0001655759-24-000128
- form_type: 8-K
- ticker: ARVN
- cik: 0001655759
- company_name: ARVINAS, INC.
- filed_at: 2024-10-30T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1655759/000165575924000128/0001655759-24-000128-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1655759/000165575924000128/arvn-20241030.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001655759-24-000128
- JSON: https://secwatch.observer/filing/0001655759-24-000128.json
- Plain text: https://secwatch.observer/filing/0001655759-24-000128.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.